Journal of Clinical Microbiology, May 1999, p. 1653-1653, Vol. 37, No. 5
0095-1137/99/$04.00+0
LETTERS TO THE EDITOR
No Confirmation of Pestivirus RNA in Human Virus Vaccines
 |
LETTER |
Recently, Harasawa and Tomiyama (1) reported the detection of
pestivirus RNA in human vaccines. The origin of the contamination was
unknown, but the vaccines had been prepared in cell cultures supplemented with bovine fetal calf serum (FCS), which can be contaminated with bovine viral diarrhea virus (BVDV).
We used a closed one-tube reverse transcription (RT)-nested PCR method
to attempt the amplification of pestivirus RNA from 30 human vaccines
produced by European companies. Six were inactivated vaccines made in
embryonated eggs and contained purified influenza viruses. Twenty-four
were live unpurified, cell culture-derived vaccines and contained
polio, measles, mumps, or rubella viruses (six samples of each). Six
control samples were also provided and contained 1% calf seurm or 1%
FCS (three samples of each). The 36 samples were tested blind in nine
batches. Each batch of testing incorporated a positive-control sample
(BVDV) and seven negative-control samples (water).
An RNA isolation procedure was carried out on all 108 samples and
controls. This involved addition of 800 µl of Trizol (Sigma) to 200 µl of sample or control, followed by processing according to the
manufacturer's recommendation. To minimize false-positive reactions,
we used a closed one-tube RT-nested PCR method developed in our
laboratory. Half of the extracted RNA was added to a tube containing RT
and first PCR mixtures, along with outer panpestivirus primers V324 and
V326. Fresh Taq DNA polymerase and inner panpestivirus primers A11 and A14 were present in the tube lid in a dry form. These
components were added to the second (nested) PCR mixture (30 cycles) by
inversion of the tube after RT and the first PCR (20 cycles). Amplified
products were examined by agarose gel electrophoresis and sequencing.
Details of this procedure will be described elsewhere and show that the
method is more sensitive than virus isolation for detection of
pestiviruses in clinical samples (2).
The method detected BVDV in two of three control samples containing 1%
FCS and in one of three samples of 1% calf serum. Sequencing two
amplicons showed that a different pestivirus had been detected in each
sample type. Both products had been declared by the supplier to be
pestivirus free. Other negative and positive controls gave the expected
results. Pestivirus RNA was not detected in any of the vaccine samples
tested. Four vaccine samples that gave suspicious results were 50×
concentrated by ultracentrifugation. Repeat testing and sequencing of
amplified products confirmed only nonspecific amplifications. Our
results demonstrate that the frequency of contamination of human
vaccines by pestiviruses may be lower than has been reported previously.
 |
ACKNOWLEDGMENTS |
Stefan Vilcek was supported by a Wellcome Trust International
Research Development fellowship.
 |
REFERENCES |
| 1.
|
Harasawa, R., and T. Tomiyama.
1994.
Evidence of pestivirus RNA in human virus vaccines.
J. Clin. Microbiol.
32:1604-1605[Abstract/Free Full Text].
|
| 2.
| McGoldrick, A., E. Bensaude, G. Ibata, G. Sharp, and D. J. Paton. Closed one-tube reverse transcription nested polymerase
chain reaction for the detection of pestiviral RNA with fluorescent
probes. J. Virol. Methods, in press.
|
| | | | |
Stefan Vilcek
Department of Infectious and Tropical Diseases University of
Veterinary Medicine Komenskeho 73 Kosice,
Slovakia
|
| | | | |
David J. Paton
Veterinary
Laboratories Agency Weybridge Woodham Ln. Addlestone, Surrey,
United Kingdom
|
| | | | |
Philip Minor
Maureen Bentley
National Institute for Biological Standards and
Controls Blanche Ln., South Mimms Potters Bar, Hertfordshire,
United Kingdom
|
Journal of Clinical Microbiology, May 1999, p. 1653-1653, Vol. 37, No. 5
0095-1137/99/$04.00+0